thumbnail
Therapeutic ClassEpisologen, Lonza manufacture first IgE to treat ovarian cancerEpisologen, Lonza manufacture first IgE to treat ovarian cancer
Epsilogen and Lonza have successfully completed large-scale GMP manufacturing of MOv18 IgE, to treat platinum-resistant ovarian cancer (PROC) patients.